List view / Grid view
16 December 2015 | By Quotient Clinical
Quotient Clinical, the Translational Pharmaceutics® company, has announced that it has acquired formulation development specialist Co-Formulate Limited...
16 December 2015 | By Victoria White
Ciclosporin (Ikervis) is a sterile, positively charged, oil-in water, unpreserved ophthalmic emulsion that contains ciclosporin (CsA)...
15 December 2015 | By Versatile Syrris
Today, scientists have access to hundreds of flow chemistry papers citing groundbreaking applications established on modular reactors from Syrris, including the Ley group’s Accelerating Spirocyclic Polyketide Synthesis using Flow Chemistry...
15 December 2015 | By Victoria White
A new fund – created through a £17m donation from GSK and £5m from Comic Relief – will provide targeted grants over the next five years to organisations on the malaria frontline...
15 December 2015 | By Victoria White
GBI Research’s latest report states that pharmaceutical companies are considering various strategies to overcome the challenge of rising R&D costs, with deal-making the foremost method of boosting short-term revenues...
15 December 2015 | By Victoria White
Viberzi, a twice daily, oral medication, is Allergan’s first-in-class treatment for irritable bowel syndrome with diarrhoea (IBS-D)...
15 December 2015 | By Victoria White
Amgen has entered into a definitive agreement with GSK to reacquire all of its remaining rights to Prolia (denosumab), XGEVA (denosumab) and Vectibix (panitumumab) in 48 countries...
15 December 2015 | By Victoria White
The proposed transaction would consist of an exchange of Sanofi animal health business (Merial) and Boehringer Ingelheim consumer healthcare (CHC) business...
14 December 2015 | By Victoria White
The trial’s primary endpoint is the percentage of patients with on-treatment gastrointestinal adverse events from baseline to week 12...
14 December 2015 | By Victoria White
Vistogard is the first and only antidote for 5-FU and capecitabine overdose and for earlyonset, severe, life-threatening toxicities approved by the FDA...
14 December 2015 | By Victoria White
The Australian Federal Court has found that Reckitt Bensicker (Australia) engaged in misleading conduct in contravention of Australia Consumer Law by representing that its Nurofen Specific Pain Products were each formulated to treat a specific type of pain...
AstraZeneca today confirmed that it is in talks with Acerta Pharma to acquire the company in a potential deal worth $5 billion.
14 December 2015 | By Cherwell Laboratories
Company boosts industrial microbiology expertise to enhance customer support...
14 December 2015 | By Victoria White
Takeda’s Ninlaro (ixazomib) capsules, the first and only oral proteasome inhibitor, are now available in the US for patients with multiple myeloma...
14 December 2015 | By Victoria White
Alecensa (alectinib) is approved for patients whose disease has worsened after, or who could not tolerate treatment with Xalkori (crizotinib)...
